Developer of oral versions of biologic therapies to be purchased by Intrexon

Biotech player Intrexon ($XON) has signed up to acquire Belgium's ActoGeniX for $60 million. The new addition is a developer of oral meds as an alternative to injectable biologics. Currently, biologic therapies cannot withstand the rigors of the acid in the stomach, so oral versions of the new-era drugs are lacking. "Utilization of living biofactories, whether through adoptive T-cell therapies, autologous fibroblast platforms or food-grade microbes, is one of the principal objects of the engineering of biology, which we aspire to lead at Intrexon," CEO R.J. Kirk said in a statement. "The outstanding team at ActoGeniX is a welcome addition to assist us in this endeavor." More

Suggested Articles

Xeris bucked pandemic trends with the July launch of its Gvoke HypoPen for hypoglycemia, boosting glucagon prescriptions across the board.

Chiasma's new acromegaly pill Mycapssa, aiming to convert patients from injectables, turned out positive 48-week data from an extension study.

Medicated chewing gum is a prime drug delivery target, but it's tough to test. An experimental set of robot jaws could ease that burden.